Skip to content

Author

R. Mak

We have 5 of 340 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

MRI-Guided Reduced-Volume RT for Early-Stage Glottic Cancer: A Prospective Phase 1 Trial with Quantification of Laryngeal Motion.

PURPOSE Five to 7 weeks of whole-larynx radiation (RT) is standard for treatment of early-stage glottic cancer. Previous studies evaluated CT-guided hypofractionated/SBRT treatment to a smaller volume. Magnetic resonance-guided radiotherapy (MRgRT) allows real-time motion tracking and gating by continuously imaging the...

J. Leeman, A. Droznin, C. D. Dwyer et al. · 0 citations
Open access Sep 2026

US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes

Aim: Lorlatinib and alectinib are next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) approved for the treatment of ALK-positive (ALK+) advanced/metastatic non-small cell lung cancer (NSCLC) after demonstrating superior efficacy over crizotinib (first-generation ALK TKI) in the CROWN and...

Adam Kasle, D. Abrahami, David L. Veenstra et al. · 0 citations
Open access Sep 2026

Validating LLM judges for automated oversight of patient communication

A stakeholder-informed seven-criterion evaluation rubric spanning safety, reliability, and communication quality is developed and benchmarked 19 LLM judges across multiple implementation strategies, supporting LLM judges for scalable patient communication oversight while demonstrating the need for recalibration to pati...

Zi-Du Xu, Johnathan Zeng, Shuang Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.